Skip to main content

Advertisement

Table 1 Patient characteristics

From: Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study

Predictora All patients
(n = 454)
Patients without AF
(n = 409)
Patients
with AF
(n = 45)
p V alue
Demographic     
   Mean age, year 65.4 ± 8.8 65.0 ± 8.9 68.6 ± 6.8 0.008
   Male, n (%) 369 (81.3) 332 (81.2) 37 (82.2) 0.864
   BMI, kg/m2 25.6 ± 4.1 25.7 ± 4.2 24.7 ± 3.3 0.116
Comorbidities     
   Paroxysmal AF, n (%) 45 (9.9) 38 (8.8) 7 (15.5) 0.182
   CAD, n (%) 56 (12.3) 45 (11.0) 11 (24.4) 0.009
   Prior AMI, n (%) 15 (3.3) 12 (2.9) 3 (6.7) 0.178
   Hypertension, n (%) 183 (40.3) 161 (39.4) 22 (48.9) 0.216
   Diabetes, n (%) 58 (12.8) 53 (13.0) 5 (11.1) 0.999
   Dyslipidemia, n (%) 71 (15.6) 60 (14.7) 11 (24.4) 0.087
   Current smokers, n (%) 182 (40.1) 164 (40.1) 18 (40.0) 0.990
   PVD, n (%) 115 (25.3) 106 (25.9) 9 (20.0) 0.386
   CVA, n (%) 19 (4.2) 16 (3.9) 3 (6.7) 0.421
Baseline biochemical data     
   Creatinine, mg/dL 1.0 ± 0.5 1.0 ± 0.4 1.2 ± 1.1 0.287
   Hb, g/dL 13.8 ± 1.6 13.8 ± 1.5 13.6 ± 1.8 0.352
Baseline respiratory data     
   FEV1, % of predicted 88.1 ± 21.9 88.2 ± 21.7 86.9 ± 24.1 0.716
   PaO2, mmHg 94.5 ± 21.9 94.3 ± 20.9 96.3 ± 29.2 0.558
Preoperative therapy     
   β-blockers, n (%) 36 (7.9) 29 (7.1) 7 (15.6) 0.046
   Calcium antagonists, n (%) 58 (12.8) 51 (12.5) 7 (15.6) 0.556
   ACE-Inhibitors, n (%) 67 (14.8) 59 (14.4) 8 (17.8) 0.547
   ARBs, n (%) 33 (7.3) 29 (7.1) 4 (8.9) 0.659
   Statins, n (%) 45 (9.9) 39 (9.5) 6 (13.3) 0.429
   Neoadjuvant chemotherapy, n (%) 30 (6.6) 28 (6.8) 2 (4.4) 0.756
  1. a For continuous variables, mean ± SD (standard deviation); for categorical variables, number (percent)
  2. ACE angiotensin converting enzyme, AF atrial fibrillation, AMI acute myocardial infarction, ARB angiotensin receptor blocker, BMI body mass index, CAD coronary artery disease, CVA cerebrovascular accident, FEV 1 forced expiratory volume in 1 second, Hb haemoglobin, PaO 2 partial arterial oxygen pressure, PVD peripheral vascular disease